New long-term data from the Phase 3 ENDEAVOR trial has shown that relapsed multiple myeloma patients treated with Kyprolis (carfilzomib) plus dexamethasone survive a median of…
Relapsed multiple myeloma patients who receive Kyprolis (carfilzomib) plus dexamethasone as their second-to-fourth treatment regimen survive a median of 7.6 months longer than those…
Patients with relapsed or treatment-resistant multiple myeloma, who have undergone several earlier treatment rounds, have a much poorer response to combination treatments including Darzalex (daratumumab)…
Newly-diagnosed multiple myeloma patients who are not eligible for a stem cell transplant reduce the risk of disease progression or death by half when Darzalex (daratumumab)…
BioLineRx is seeking regulatory approval to advance into a Phase 3 clinical trial its treatment BL-8040, for blood stem cell mobilization to prepare for autologous…
Kite Pharma has submitted an investigational new drug application to the U.S. Food and Drug Administration that would pave the way toward clinical trials of its…
Combining the proteasome inhibitor Kyprolis (carfilzomib) with dexamethasone is beneficial for adult patients with multiple myeloma who have received…
Myeloma patients who received a single dose of the investigational therapy CLR 131 in an ongoing Phase 1 clinical trial have reached a median overall…
Newly diagnosed multiple myeloma patients who use Revlimid (lenalidomide) as a maintenance therapy after a stem cell transplant live significantly longer than those receiving a placebo…
PharmaMar is launching a clinical trial to explore its investigational therapy Aplidin (plitidepsin) in a quadruple combination treatment for multiple myeloma. The four compounds involved…
